Biography

Mr. Kango is an experienced executive with more than 26 years of experience in the pharmaceutical and biotechnology sector. Mr. Kango is the Co-Founder of Oorja Bio and has served as its President and CEO since September 2023. His vast, results-oriented experience ranges from serving as both public and private company board member to being a C-suite executive of multi-billion dollar public companies. He previously served on the boards of Adante, Inc., MEI Pharma and Infinity Pharmaceuticals. Mr. Kango was the President and Chief Executive Officer of Tmunity Therapeutics, a clinical stage research and development CAR-T therapy company that was acquired by Gilead Sciences in February 2023 for an undisclosed amount. From 2018-2021, he served as the EVP, Chief Commercial Officer of Acceleron Pharma, which was acquired by Merck & Co. for over $11.5 billion. Mr. Kango has been responsible for over 5 blockbuster products and launches, including Reblozyl, Nexavar, Kyprolis, Peg-Intron, and Remicade. He earned a B.S. in Microbiology and an M.B.A. from McNeese State University.